Overview
Cogent Q2 net loss widens to $73.5 mln from nearly $59.0 mln yr ago
Bezuclastinib shows statistically significant results in SUMMIT trial
Co's cash position expected to fund operations through 2027, including launch
Outlook
Company projects cash runway into 2027
Result Drivers
R&D COSTS: R&D expenses increase mainly due to costs incurred to support on-going SUMMIT, PEAK and APEX clinical trials
FINANCIAL POSITION - Cogent's cash position, strengthened by a recent public offering, is expected to support operations through 2027
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income |
| -$73.53 mln |
|
Q2 Income from Operations |
| -$75.58 mln |
|
Q2 Operating Expenses |
| $75.58 mln |
|
Press Release: ID:nGNX6VtWgC